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Gentamicin is an aminoglycoside antibiotic widely used in combination 
with dimethyl sulphoxide (DMSO) in topical drug formulations. It is not known, 
however, whether DMSO can enhance the permeation of gentamicin through bio-
logical membranes, leading to oto- and nephrotoxic side effects. A simple and re-
liable high-performance liquid chromatographic (HPLC) method was applied for 
the quantitative determination of gentamicin collected from the apical and baso-
lateral compartments of the porcine intestinal epithelial cell line IPEC-J2 cell 
monolayer using fluorometric derivatisation of the analyte with fluorenylmethy-
loxycarbonyl chloride (FMOC) prior to chromatographic run in the presence and 
absence of 1% DMSO. The lack of change in transepithelial electrical resistance 
(TER) demonstrated that gentamicin and 1% DMSO did not affect IPEC-J2 cell 
monolayer integrity via the disruption of cell membranes. Chromatographic data 
also ascertained that gentamicin penetration across the cell monolayer even in the 
presence of 1% DMSO was negligible at 6 h after the beginning of apical gen-
tamicin administration. This study further indicates that the addition of this or-
ganic solvent does not increase the incidence of toxic effects related to gentamicin 
permeation. 
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Gentamicin is one of the most potent aminoglycoside antibiotics com-
monly used in veterinary and human medicine for the treatment of infections 
caused mainly by Gram-negative aerobic bacteria and staphylococci. Under cer-
tain physiological and pathological conditions, however, its systemic use is oto-
toxic and nephrotoxic, and thus it cannot be administered to young or dehydrated 
animals and to patients with renal insufficiency. In the companion animal prac-
tice, gentamicin is often administered topically in the form of suspensions, 
creams, ointments or ear drops, if the tympanic membrane is still intact (Par-
ravicini et al., 1982; Oghan et al., 2011). Direct contact with the inner ear at high 
local concentrations can result in severe irreversible ototoxic effects (El Bakri et 
al., 1998). A higher incidence of ototoxicity was reported in animals than hu-
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mans (Morizono, 1988) following topical administration of gentamicin as an ear 
drop. 
Gentamicin can also cause systemic toxic effects if it is absorbed through 
biological membranes such as the tympanic membrane, the conjunctiva or the in-
testinal epithelium. Although the oral bioavailability of gentamicin is usually less 
than 3% in healthy animals, oral uptake might also be a toxicological issue if 
topical preparations containing the surfactant dimethyl sulphoxide (DMSO) are 
consumed and ingested by animals, although even DMSO concentrations as high 
as 10% did not have an effect on the permeability of the apical membrane or 
tight junctional complexes in Caco2/TC7 cells (Da Violante et al., 2002). There-
fore, it is important to determine if DMSO supplementation increases the trans-
port of gentamicin across cell layers, which would increase the potential toxic ef-
fects of this aminoglycoside. 
Structurally, gentamicin is a 4,6-disubstituted aminocyclitol composed of 
the core aminocyclitol moiety 2-deoxystreptamine (2-DOS), which is comple-
mented with purpurosamine and garosamine aminosugars at positions C-4 and C-
6, respectively (Fig. 1). In its therapeutic form, gentamicin comprises a complex 
of gentamicin C1, C1a and C2, which differ only in the degree of methylation of 
the C-6’ position of the sugar attached at C-4 of 2-DOS (Testa and Tilley, 1976). 
The other component of gentamicin is C2a, which is a 6’-C epimer of C2 (Seidl 
and Nerad, 1988). Several papers on high-performance liquid chromatographic 
(HPLC) methods (Isoherranen et al., 2000; Al-Amoud et al., 2002) with fluoro-
metric detection have been published for the quantitative determination of the 
gentamicin complex consisting of closely related compounds such as C1, C1a, C2 
and C2a. Among derivatisation techniques, o-phthalaldehyde (OPA) and fluo-
renylmethyloxycarbonyl chloride (FMOC) are frequently applied to detect gen-
tamicin in complex biological matrices. In our model system, the IPEC-J2 cell 
line was grown on microporous membranes to ensure spontaneous cell differen-
tiation, which is a prerequisite for studying the transport processes through polar-
ised epithelial monolayer present between the apical and basolateral compartments 
(Tremblay et al., 2006; Cencic and Langerholc, 2010; Langerholc et al., 2011). 
The transcellular permeation of gentamicin is practically not possible in 
view of its relatively high molecular weight and highly polar and hydrophilic na-
ture (Rama Prasad et al., 2003). Paracellular permeation across tight junctions, 
however, might occur (Madara, 1989; González-Mariscal et al., 2003), and 
DMSO can facilitate this process by modulating protein assembly in tight junc-
tions. At higher concentrations, DMSO is known to disrupt lipid structures in 
epithelia (Gordeliy et al., 1998; Simons, 2008) and thus it can facilitate the pene-
tration of certain substances. It was previously described that labrasol, a non-
ionic surfactant, enhanced the oral bioavailability of gentamicin (Hu et al., 2001) 
probably via tight junction opening mechanisms. 
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Gentamicin C1 R1 = R2 = CH3 R3 = H 
Gentamicin C1a R1 = R2 = R3 = H 
Gentamicin C2a R1 = R2 = H R3 = CH3 
Gentamicin C2 R1 = CH3 R2 = R3 = H
Fig. 1. Chemical structure of gentamicin complex: C1, C1a, C2 and C2a 
 
The aim of this study was to determine the permeation of gentamicin 
across a monolayer of the porcine intestinal epithelial cell line, IPEC-J2 in the 
presence and absence of 1% DMSO using HPLC with fluorescence detection 
based on derivatisation of the analyte with fluorenylmethyloxycarbonyl chloride 
(FMOC). The results can contribute to an in-depth prediction of the topical or 
oral absorption of gentamicin in the presence of DMSO. 
 
 
Materials and methods 
The IPEC-J2 cell line used in this study was derived from jejunal epithelia 
of a neonatal piglet and was a kind gift from Dr. Jody Gookin, North Carolina 
State University, USA. It is a non-transformed cell line that in some respects 
mimics in vivo conditions when cultured on membrane inserts. Cells form a dif-
ferentiated monolayer and are attached to each other via tight junctions apically. 
The high transepithelial electrical resistance (TER) of IPEC-J2 monolayers 
grown on Transwell polyester filters coated with rat tail collagen shows the func-
tional integrity of a continuous, uninterrupted cell layer. Only monolayers with a 
TER value of at least 8,000 Ohm/cm2 were used as a model system to study the 
cellular barrier permeability. The cells were maintained in a complete medium 
containing 1:1 mixture of Dulbecco’s Modified Eagle’s Medium and Ham’s F-12 
Nutrient Mixture (DMEM/F12) supplemented with 5% FBS, 5 μg/ml insulin, 
5 μg/ml transferrin, 5 ng/ml selenium, 5 ng/ml epidermal growth factor and 1% 
penicillin-streptomycin (all from Fisher Scientific, USA). Cell cultures were 
tested by PCR and were found to be free of mycoplasma contamination. IPEC-J2 
cells were seeded at a density of 1.5 × 105 per well on six-well plates with Tran-
swell polyester membrane inserts (pore size: 0.4 μm; surface area: 4.67 cm2; 
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Sigma, Germany) coated with rat tail collagen (Sigma) in a 1.5-ml apical and 
2.6-ml basolateral volume. Cells were allowed to adhere for 24 h before being 
washed and re-fed every other day until confluence. They were grown at 37 °C 
in a humidified atmosphere of 5% CO2 for three weeks before the experiments. 
Three replicas were used for each treatment. 
Prior to the treatments, IPEC-J2 cells were washed twice with plain me-
dium (complete medium without FBS and antibiotics). Six-well inserts were 
treated apically with 1 mg/ml of gentamicin sulphate (Sigma) and with gen-
tamicin sulphate supplemented with 1% DMSO (Sigma) dissolved in plain me-
dium. The basolateral compartments of the Transwell inserts were filled with 
plain medium. Treatment lasted for 1 and 6 h, and TER was measured at differ-
ent time points (before treatment and 6 h after treatment). One ml from each api-
cal and basolateral medium was collected at different time points (0 h, 1 h, 6 h), 
diluted in PBS and the amount of gentamicin present in the apical and basolateral 
compartments was determined by HPLC. 
For the determination of gentamicin concentration in the apical and baso-
lateral compartments, a Merck LaChrome Elite HPLC system with a Spherisorb 
ODS-2 (5 μm pore size, 250 × 4.6 mm) column was used with fluorescent detec-
tion and an eluent consisting of 85% acetonitrile and 15% ultra-pure water. The 
temperature of the column and the autosampler was 25 °C and 20 °C, respec-
tively. The excitation and emission wavelengths of fluorescent detection were 
260 nm and 315 nm, respectively. Flow rate was 1 ml/min, injection volume was 
25 μl and the running time was 34 min. Preparation of standards (2, 1, 0.5, 0.2 
and 0.1 µg/ml) was achieved with the dilution of 50 mg/ml gentamicin sulphate 
(Sigma) standard with ultra-pure water and a diluent consisting of 50% acetoni-
trile (Prolabo, Thailand) and 50% borate buffer (Merck, Germany). The peak area 
and the concentration showed a good linear relationship, while the concentration 
of gentamicin was between 0.1 μg/ml and 2 μg/ml, r2 = 0.9997. DMEM/F12 me-
dium and DMEM/F12 supplemented with 1% DMSO were used as blank. Deri-
vatisation was achieved with 10 mM fluorenylmethyloxycarbonyl chloride (Merck) 
solution for 15 min. The reaction was stopped with 0.1 M glycine solution 
(Merck). The method was validated, the limit of detection (LOD) was 0.19 ng/ml 
and the limit of quantification (LOQ) was 0.63 ng/ml, indicating the high sensi-
tivity of the method. 
An unpaired, two-sample Student’s t-test was used for the statistical 
analysis. 
 
Results and discussion 
Previous studies have shown that IPEC-J2 cells are able to differentiate 
with a parallel expression of tight junction proteins and increasing TER values 
(Schierack et al., 2006), forming a cell monolayer that acts as a barrier against 
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polar substances of high molecular weight. Claudins and E-cadherin have been 
considered as key integral protein regulators responsible for the maintenance of 
electrical resistance and paracellular integrity (Oliveira and Morgado-Diaz, 
2007). Previous findings indicate that certain solvents, like the surfactant labra-
sol, can disrupt tight junction integrity, and thus enhance the penetration of gen-
tamicin across membranes (Hu et al., 2001). This phenomenon was not observed 
when gentamicin was supplemented with another solvent, 1% DMSO. 
To assess the effect of the substances on the integrity of the cell monolayer, 
TER was determined before and after the treatment. TER was measured and was 
consistently above 8,000 Ohm/cm2 before treatment and 6 h after treatment. Fig-
ure 2 shows the observed TER values of gentamicin and gentamicin + 1% DMSO 
treated IPEC-J2 cell cultures before and after 6 h of treatment. 
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Fig. 2. Transepithelial electric resistance (TER) values before treatment and after 6 hours of treat-
ment with 1 mg/ml gentamicin and 1 mg/ml gentamicin supplemented with 1% DMSO (mean ± SD) 
 
There was no significant difference (P > 0.05) between TERs before the 
treatment and 6 h after treatment with gentamicin or gentamicin in 1% DMSO, 
thus it is assumed that cell integrity was damaged neither by 1 mg/ml gentamicin 
nor by gentamicin supplemented with 1% DMSO. TER values show that neither 
gentamicin nor gentamicin supplemented with 1% DMSO alters tight junction 
formation and paracellular integrity. It was previously described (Konari et al., 
1995) that DMSO can even induce the expression of tight junction proteins and 
thus increase TER values. At the low concentration of DMSO used in this study, 
this phenomenon was not observed. 
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Table 1 shows the transport of gentamicin in the presence and absence of 
1% DMSO in the insert without cells and across the IPEC-J2 cell monolayer. In 
wells without cells, an almost total equilibrium in gentamicin concentration was 
achieved after 6 h between apical and basolateral compartments. Addition of 1% 
DMSO did not alter gentamicin transport significantly (P > 0.05). The membrane 
insert served as a time-dependent barrier as it delayed the equilibration of gen-
tamicin concentrations between the two compartments. In wells with cell 
monolayer, no gentamicin was detected in the basolateral compartment either in 
wells treated with gentamicin or in wells treated with gentamicin + 1% DMSO, 
1 h after treatment, and the total gentamicin content was detected in the apical 
region (Fig. 3). Six h after treatment, a very low amount of gentamicin was 
measured in the basolateral compartment. No significant difference (P > 0.05) 
was observed in gentamicin levels in wells treated with gentamicin alone or in 
combination with 1% DMSO. Thus, gentamicin shows poor transcellular and 
paracellular permeation across a cell monolayer in vitro. DMSO added in 1% 
concentration did not enhance the permeation of the aminoglycoside through cell 
monolayers. Therefore, it can be assumed that 1% DMSO does not significantly 
alter gentamicin penetration across monolayer biological membranes in vitro. 
The results of TER and HPLC measurements prove that DMSO in 1% concentra-
tion does not alter paracellular integrity and thus gentamicin permeation in 
IPEC-J2 cells. 
Table 1 
Concentrations of gentamicin (%) in apical and basolateral compartments in wells containing 
IPEC-J2 cell monolayer and in control wells contaning no cells 
Insert without cells Cell monolayer 
Treatment Time h 
Apical 
compartment 
(%) 
Basolateral 
compartment 
(%) 
Apical 
compartment 
(%) 
Basolateral 
compartment  
(%) 
Gentamicin 0 99.85 ± 0.24 0.00 ± 0.29 98.36 ± 0.90 0.15 ± 0.12 
 1 72.38 ± 1.07* 26.47 ± 1.52* 99.13 ± 0.85 0.05 ± 0.23 
 6 52.13 ± 0.53* 46.81 ± 0.32* 99.94 ± 0.01 1.12 ± 0.81 
Gentamicin in 1% DMSO 0 99.65 ± 0.62 0.15 ± 0.29 99.54 ± 0.21 0.41 ± 0.08 
 1 72.67 ± 1.15* 27.12 ± 1.29* 98.56 ± 0.91 0.11 ± 0.05 
 6 54.45 ± 1.23* 44.98 ± 1.31* 99.93 ± 0.02 0.05 ± 0.01 
Explanations: 100% represents initial apical gentamicin concentration. Significant differences (*P < 
0.05) in gentamicin permeation were found between initial value at t = 0 h and t = 1 h or t = 6 h 
when insert was not covered with cell layer. Data are shown as means ± SEM (n = 6) 
 
Ear drops containing gentamicin are often used in human and veterinary 
medicine for the treatment of external otitis since staphylococci and Pseudomo-
nas aeruginosa are frequently present in such conditions. Because of a potential 
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irreversible ototoxic effect (Matz et al., 2004), gentamicin-containing products 
cannot be used in cases with a perforated tympanic membrane (Rosenfeld et al., 
2006). Although the present studies were conducted on monolayer IPEC-J2 cells, 
our results suggest that gentamicin alone or supplemented with 1% DMSO can-
not penetrate through the intact tympanic membrane into the inner ear. The tym-
panic membrane is coated with a striated multilayered epithelium, thus offering 
further protection from the potential ototoxic effect of gentamicin. The tight bar-
rier due to IPEC-J2 cells grown in a monolayer and linked by tight junction pro-
teins is less complex than the multilayered tympanic membrane, and therefore 
our approach is over-predictive. Furthermore, our data show that the addition of 
the organic solvent DMSO did not alter the transport of gentamicin through an 
intestinal epithelial monolayer, hence it might not enhance the oral absorption of 
gentamicin if ingested accidentally. Whether our in vitro results can be extrapo-
lated to the in vivo situation remains to be investigated. 
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Fig. 3. Representative chromatogram of gentamicin complex collected from the apical compart-
ment of the IPEC-J2 cell monolayer. The order of elution with mobile phase (85% ACN,  
15% UPW) was gentamicin C1 (tret = 21.89 min), gentamicin C1a (tret = 24.7 min), gentamicin C2a 
(tret = 25.67 min) and gentamicin C2 (tret = 28.42 min). The fluorescence detection wavelengths 
were 260 nm (excitation λ) and 315 nm (emission λ). The flow rate was adjusted to 1 ml/min 
 
In conclusion, gentamicin showed poor paracellular permeation across the 
IPEC-J2 monolayer. Addition of 1% DMSO did not disrupt paracellular integrity 
and did not alter the transport of gentamicin. Our results indicate that the inclu-
sion of DMSO in this low concentration as part of the drug formulation does not 
promote the oral absorption of gentamicin and it does not enhance the incidence 
of ototoxic effects caused by gentamicin in ear drop application. In the future, 
gentamicin can be used for detecting epithelial barrier dysfunction during LPS-
induced bacterial infection or acute oxidative stress when chromatographic sepa-
ration and quantitative fluorometric determination of gentamicin collected from 
basolateral compartment of IPEC-J2 cell monolayer is performed. 
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